Tags
Boston, DePuy, FDA, Federal Food Drug and Cosmetic Act, Food & Drug Administration, Institute of Medicine, Medical device, Reuters
U.S. advisers call for new medical device regime
WASHINGTON (Reuters) – An advisory group said the U.S. fast-track approval process for medical devices is fatally flawed and should be replaced, but the Food and Drug Administration said the recommendation was a non-starter.
The FDA had asked for the Institute of Medicine report as part of a broad agency review of its device unit, an area dogged by high staff turnover, funding woes and major recalls in recent year of devices ranging from artificial hips to heart defibrillators.
The IOM found the fast-track approval process, called 510(k), does not adequately protect patients and recommended a more thorough approval process likely to raise the costs for device makers with pre-market and post-market device reviews.
“What we are recommending is that the 510(k) is fatally flawed in terms of it not evaluating safety and effectiveness of a device,” said Dr. David Challoner, chairman of the IOM’s committee.
But the finding was swiftly rejected by the FDA’s top device official.
“FDA believes that the 510(k) process should not be eliminated, but we are open to additional proposals and approaches for continued improvement of our device review programs,” Dr. Jeffrey Shuren, director of the FDA’s Center for Devices and Radiological Health, said in a statement.
The 510(k) program allows medical devices to get to market faster if they are “substantially equivalent” to an existing product.
Critics say the accelerated 510(k) process is too widely used and leads to inadequate testing for some risky devices, but it is defended by the industry as necessary to speed technologies to patients.
The medical device industry has argued for either leaving the 510(k) process as it is or further streamlining the approval process. Most new medical devices — about 4,000 in 2009 — are cleared through the accelerated program.
The FDA has proposed changes, including the possibility of creating a new category of more risky devices that would require more data to win approval.
But the IOM committee said the FDA should not waste its limited resources on changing the current program. Instead, the committee said the FDA should focus on developing a new framework.
High-profile incidents include a massive recall last year of artificial hips by Johnson & Johnson’s DePuy unit. Some 93,000 patients worldwide had that line of hip implant.
Automated external defibrillators, used in public places such as airports to revive cardiac arrest victims, have also made up a significant portion of 510(k) recalls in recent years. Health officials are looking at thousands of reports of malfunctions which may have led to patient harm or death.
Medical devices range from simple bandages to complex implants such as pacemakers, stents and artificial knees. Other than Johnson & Johnson, the largest medical-device makers include Medtronic Inc, Boston Scientific Corp and Abbott Laboratories Inc.
The IOM suggested the FDA start collecting information to build the new process, including post-market data for devices. Congress should then enact legislation to design the regulatory framework, according to the report.
“A new system needs to be put in place that will be more effective especially in post-market surveillance,” said Challoner.
(Reporting by Andrew Seaman; Additional reporting by Alina Selyukh; Editing by Tim Dobbyn)
Related articles
- Report could sway FDA device review process (earlsview.com)
- Institute of Medicine – Public Health Effectiveness of the FDA 510(k) Clearance Process (earlsview.com)
- 510(k) reforms: FDA downplays the impact of the IOM study on the eve of its release (earlsview.com)
- Barry Meier – Study Faults Approval Process for Medical Devices (earlsview.com)
- FDA 510K Process – Another Issue – Risky pelvic mesh highlights worries about FDA process (earlsview.com)
- Report: IOM review of the FDA 510(k) process due Friday (earlsview.com)
- Regulatory Reform Series #5 – FDA Medical Device Regulation: Impact on American Patients, Innovation and Jobs (earlsview.com)
- U.S. advisers call for overhaul of FDA device approval process (msnbc.msn.com)
- Medical-device review system doesn’t do its job, FDA told (seattletimes.nwsource.com)
- FDA clarifies when medical device changes call for new 510(k) submission (medcitynews.com)
Pingback: Australian TGA – Reforms in the medical devices regulatory framework « Earl's View
Pingback: Australian TGA – Reforms in the medical devices regulatory framework: Overview of submissions « Earl's View
Pingback: FDA Seeks Public Views on Proposed 510(k) Plans « Earl's View
Pingback: Did IOM Put the Final Nail in the Coffin of Metal-on-Metal Hip Implants? « Earl's View
Pingback: How Safe Are Medical Devices? « Earl's View
Pingback: IOM Gives FDA The wrong prescription on medical devices & 510(k) « Earl's View
Pingback: Medical Devices — Balancing Regulation and Innovation « Earl's View
Pingback: FDA Enforcement Reports documented 233 medical device recalls involving nearly 16 million units « Earl's View
Pingback: Medical Device Aproval – Divisive Devices or UFC 510(k): FDA Meets IOM « Earl's View
Pingback: IOM chair discusses 510(k) report: origins, findings, response « Earl's View
Dear writer, your great ideas are the best of all articles i’ve read. I love your post it helped me a lot. Thanks.
http://hiprecalllawyers.com